ISSN (Print) - 0012-9976 | ISSN (Online) - 2349-8846
-A A +A

Ranbaxy Sell-out: Reversal of Fortunes

The Ranbaxy sale to Daiichi Sankyo could herald a new phase in the evolution of the Indain pharmaceutical industry. In order to cope in a world after the agreement on Trade-related Aspects of Intellectual Property Rights came into force, some of the larger Indian firms pursued the two strategies of a greater internationalisation of sales of generic drugs and a focus on research and development as junior partners of global giants. Ranbaxy had mixed success with the two strategies. In recent years Ranbaxy found itself increasingly squeezed in both areas and was therefore left with little choice but to sell out. The issue once again then is to stretch the flexibilities in TRIPS and renegotiate the agreement - essential if the Indian industry is to remain healthy and prices kept under check.

Subscribers please login to access full text of the article.

New 3 Month Subscription
to Digital Archives at

826for India

$50for overseas users

Get instant access to the complete EPW archives

Subscribe now

Comments

(-) Hide

EPW looks forward to your comments. Please note that comments are moderated as per our comments policy. They may take some time to appear. A comment, if suitable, may be selected for publication in the Letters pages of EPW.

Back to Top